11 completed, 2 terminated. 5 Phase 2, 4 Phase 3, 2 Not applicable, 2 Phase 1.
By phase and status
Follow alisporivir: new trials by email Literature Review of alisporivir trials Research Report on alisporivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)
Alisporivir, Standard of care (SOC) - SARS-CoV-2 | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 26 | 2021-01-08 | 2023-05-11 |
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
Alisporivir, Ribavirin - Hepatitis C, Liver Disease | Phase 2 | Completed | Debiopharm International SA | 52 | 2014-03-01 | 2016-10-13 |
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
Alisporivir, Ribavirin, Peg-IFNα2a - Hepatitis C, Liver Disease | Not applicable | Completed | Debiopharm International SA | 147 | 2013-10-01 | 2016-04-20 |
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
Alisporivir - Kidney Failure, Chronic | Phase 1 | Completed | Debiopharm International SA | 16 | 2013-08-01 | 2016-08-17 |
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
Alisporivir, Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Terminated | Debiopharm International SA | 6 | 2012-03-01 | 2016-08-01 |
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
Alisporivir, Boceprevir, Peginterferon alfa-2a - Hepatitis C | Phase 3 | Terminated | Debiopharm International SA | 8 | 2011-12-01 | 2017-01-16 |
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
Alisporivir - Hepatitis C | Phase 3 | Completed | Debiopharm International SA | 723 | 2011-12-01 | 2016-08-26 |
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
Alisporivir - Hepatic Insufficiency | Phase 1 | Completed | Debiopharm International SA | 32 | 2011-03-01 | 2016-04-28 |
Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
Alisporivir, Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Completed | Debiopharm International SA | 1081 | 2011-03-01 | 2016-09-30 |
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
Alisporivir, Peginterferon alfa-2a, Ribavirin - Hepatitis C, Chronic Pain | Phase 2 | Completed | Debiopharm International SA | 340 | 2010-10-01 | 2016-08-30 |
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
Alisporivir, Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 2 | Completed | Debiopharm International SA | 459 | 2010-08-01 | 2016-08-25 |
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
Debio 025, Peg-IFNα2a, Ribavirin - Chronic Hepatitis C | Not applicable | Completed | Debiopharm International SA | 290 | 2009-01-01 | 2016-02-17 |
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Debio 025, Peg-IFNα2a, Ribavirin - Chronic Hepatitis C | Phase 2 | Completed | Debiopharm International SA | 50 | 2007-09-01 | 2016-02-17 |
Conditions studied
Hepatitis C (10) · Hepatitis C, Chronic (7) · Hepatitis (2) · Liver Diseases (2) · Chronic Pain (1) · Hepatic Insufficiency (1) · Kidney Failure, Chronic (1) · Lymphoma, Follicular (1)
Sponsors
Debiopharm International SA (12) · Assistance Publique - Hôpitaux de Paris (1)
Countries
United States (10) · France (8) · Germany (7) · Italy (6) · Poland (6) · United Kingdom (6) · Belgium (5) · Spain (5) · Australia (4) · Canada (4) · Puerto Rico (4) · Romania (4) · Taiwan (4) · Hungary (3) · South Korea (3)
Results publications
PMID 26118427
NIH funding
2008 (1)